XNAS
NVNO
Market cap5mUSD
Oct 08, Last price
8.18USD
1D
-2.68%
1Q
-28.04%
IPO
-99.81%
Name
enVVeno Medical Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Irvine, California, enVVeno Medical Corporation operates as a clinical-stage medical technology company. Its core mission revolves around pioneering advanced bioprosthetic tissue solutions aimed at elevating the standard of care for patients suffering from venous diseases. The company's flagship innovation is the VenoValve, a surgical implant engineered to address Chronic Venous Insufficiency (CVI). This device is surgically placed within the femoral vein, where it acts as a unidirectional valve, effectively re-establishing healthy blood flow in the leg. Complementing this, enVVeno is also developing enVVe, a non-invasive, transcatheter-delivered venous valve replacement, also intended for CVI treatment. Founded in 1999, the company underwent a name change in October 2021, transitioning from its former identity as Hancock Jaffe Laboratories, Inc.
Key people
Chief Financial Officer · since 2025
Marc Glickman
Senior Vice President, Chief Medical Officer · since 2017
Hamed Alavi
Senior Vice President, Chief Technology Officer · since 2023
Robert Berman
Chief Executive Officer, Director · since 2018
Francis Duhay
Independent Director · since 2018
Robert Gray
Independent Director · since 2019
Matthew Jenusaitis
Independent Director · since 2019
Sanjay Shrivastava
Independent Director · since 2018
Legal address
C/O Corporation Service Company
251 Little Falls Drive
Wilmington, DE 19808
US
251 Little Falls Drive
Wilmington, DE 19808
US
Headquarters
70 Doppler
Irvine, CA 92618
US
Irvine, CA 92618
US
Previous name
Hancock Jaffe Laboratories, Inc.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||